CAPA In-vitro Oocyte Maturation (CUHK Medical Centre Limited)

The Chinese University of Hong Kong

Status: Not yet enrolling

Conditions: Infertility, Female

Treatments: Other: CAPA-IVM

Study type: Interventional

Funder types: Other

Identifiers

NCT07083427

CREC-202514

Details and patient eligibility

About

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

Enrollment: 50 estimated patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients aged from 18-50 years old
• Patients seek fertility preservation services
• Patients seek oocyte retrieval services

Exclusion criteria

• Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

CAPA-IVM

Experimental group

Description:

In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

Treatment:

Other: CAPA-IVM